Neutropenia and Survival in Early Breast Cancer
Author Information
Author(s): Cameron D A, Massie C, Kerr G, Leonard R C F
Primary Institution: Department of Oncology, Edinburgh University
Hypothesis
Patients with evidence of neutropenia while on a totally intravenous CMF regimen would have a better survival than similar patients for whom there was no evidence of myelotoxicity.
Conclusion
Women with moderate neutropenia during chemotherapy had significantly better survival rates.
Supporting Evidence
- Patients with grade 2/3 neutropenia had an 82% 5-year survival rate compared to 68% for those with grades 0, 1, and 4.
- Neutropenia was documented in 10% of patients, with a significant trend for higher grades in older patients.
- Overall survival was significantly better for patients experiencing neutropenia during treatment.
Takeaway
If women with breast cancer get a little sick from their treatment, it might actually help them live longer.
Methodology
Retrospective analysis of 750 patients treated with six cycles of intravenous CMF chemotherapy for early breast cancer.
Potential Biases
Potential bias in patient selection and treatment delivery.
Limitations
The study is retrospective and may not account for all variables affecting survival.
Participant Demographics
Median age was 47.9 years, with a majority being premenopausal and stage II disease.
Statistical Information
P-Value
<0.0001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website